Antiestrogen Binding Site and Estrogen Receptor Mediate Uptake and Distribution of 4-Hydroxytamoxifen-Targeted Doxorubicin−Formaldehyde Conjugate in Breast Cancer Cells
作者:Patrick J. Burke、Brian T. Kalet、Tad H. Koch
DOI:10.1021/jm049496b
日期:2004.12.1
de conjugates possess substantially enhanced activity in vitro and in vivo. We have recently reported the design, synthesis, and preliminary evaluation of a doxorubicin-formaldehyde conjugate targeted, via 4-hydroxytamoxifen, to the estrogen receptor (ER) and antiestrogen binding site (AEBS), which are commonly present in breast cancer cells. The lead targeted doxorubicin-formaldehyde conjugate, called
蒽环类抗肿瘤药阿霉素(DOX)长期以来一直用作广谱化疗药物。现在,文献记录了甲醛在细胞毒性机制中的作用,蒽环甲醛-甲醛偶联物在体外和体内均具有显着增强的活性。我们最近报道了通过4-羟基他莫昔芬靶向于乳腺癌细胞中常见的雌激素受体(ER)和抗雌激素结合位点(AEBS)的阿霉素-甲醛缀合物的设计,合成和初步评估。发现相对于临床阿霉素和非靶向对照偶联物,尤其是在ER阴性,多药耐药的MCF-7 / Adr细胞中,铅靶向的阿霉素-甲醛偶联物称为DOX-TEG-TAM,具有优异的细胞生长抑制特性。在缺乏雌激素受体的情况下增强的活性增加了靶向也通过AEBS介导的可能性。ER阴性,AEBS阳性细胞系的荧光显微镜显示时间的函数,表明最初的DOX-TEG-TAM在细胞质中定位,这与最初的DOX和未靶向的阿霉素-甲醛共轭物在细胞核中的定位相反。DOX-TEG-TAM被四个AEBS阳性细胞系吸收的程度大于阿霉素和未